ResearcherCity of HopeActive in the last 2 years

Douglas Dias e Silva

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9536-6504; OpenAlex author ID A5082452459. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper

Papers 2

Neoadjuvant treatment for pancreatic cancer: Controversies and advances. Co-author DOI 10.1016/j.ctarc.2024.100804 ↗
Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials. First author DOI 10.1016/j.esmoop.2022.100771 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Vincent M. Chung · 1 shared paper, 2024 · strength 0.46
- Paper Neoadjuvant treatment for pancreatic cancer: Controversies and advances. DOI 10.1016/j.ctarc.2024.100804 ↗
Mitesh J. Borad · 1 shared paper, 2023 · strength 0.19
- Paper Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analy… DOI 10.1016/j.esmoop.2022.100771 ↗
Fernando Moura · 1 shared paper, 2023 · strength 0.19
- Paper Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analy… DOI 10.1016/j.esmoop.2022.100771 ↗
Pedro Luiz Serrano Usón · 1 shared paper, 2023 · strength 0.19
- Paper Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analy… DOI 10.1016/j.esmoop.2022.100771 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.